Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Rating of “Hold” from Brokerages

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has been given a consensus rating of “Hold” by the twelve analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $36.36.

Several brokerages recently commented on TNDM. Stifel Nicolaus raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and raised their target price for the stock from $24.00 to $37.00 in a research report on Tuesday, March 26th. Citigroup lifted their target price on Tandem Diabetes Care from $25.00 to $31.00 and gave the company a “neutral” rating in a research report on Friday, March 15th. Finally, StockNews.com raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Thursday, March 21st.

Institutional Investors Weigh In On Tandem Diabetes Care

Several institutional investors have recently added to or reduced their stakes in the business. Eminence Capital LP increased its position in shares of Tandem Diabetes Care by 76.1% in the third quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock valued at $114,028,000 after buying an additional 2,372,458 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Tandem Diabetes Care by 4.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 367,011 shares of the medical device company’s stock worth $7,623,000 after acquiring an additional 16,586 shares in the last quarter. Paradice Investment Management LLC boosted its position in shares of Tandem Diabetes Care by 23.9% in the 3rd quarter. Paradice Investment Management LLC now owns 1,520,065 shares of the medical device company’s stock valued at $31,572,000 after purchasing an additional 293,250 shares during the period. Banque Pictet & Cie SA acquired a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at about $2,295,000. Finally, Jennison Associates LLC boosted its position in shares of Tandem Diabetes Care by 252.6% in the 3rd quarter. Jennison Associates LLC now owns 1,122,915 shares of the medical device company’s stock valued at $23,323,000 after purchasing an additional 804,488 shares during the period.

Tandem Diabetes Care Trading Up 0.3 %

TNDM opened at $35.41 on Monday. Tandem Diabetes Care has a 52-week low of $13.82 and a 52-week high of $43.51. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91. The firm has a market capitalization of $2.32 billion, a P/E ratio of -10.29 and a beta of 1.08. The firm’s 50 day moving average is $26.97 and its 200-day moving average is $23.67.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. The company had revenue of $196.80 million during the quarter, compared to analyst estimates of $204.86 million. Analysts expect that Tandem Diabetes Care will post -1.62 EPS for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.